EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rationale and Design of the TRIC-I-HF-DZHK24 (TRICuspid Intervention in Heart Failure) Trial

Thomas J Stocker, Tobias Geisler, Wolfgang Rottbauer, Edith Lubos, Christian Frerker, Niklas Schofer, Johanne Frank, Ralph Stephan von Bardeleben, Tobias Kister, Rico Osteresch, Alexander Lauten, Tienush Rassaf und 12 weitere

European Journal of Heart Failure · 2025

DOI: 10.1002/ejhf.3795 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Heart Failure, 2025. Verfasst von Thomas J Stocker und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Department of Medicine I, LMU University Hospital, LMU Munich, Munich, Germany. Hauptthemen laut MEDLINE: Cardiac Catheterization, Heart Failure, Heart Valve Prosthesis Implantation, Quality of Life. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Tricuspid regurgitation (TR) is a detrimental disease frequently diagnosed in patients with right-sided heart failure (HF). While transcatheter tricuspid valve interventions (TTVI) effectively reduce TR and improve quality of life (QoL) in earlier stages of the disease, their effect on reducing HF hospitalizations (HFH) and improving survival remains unclear.

Methods

TRIC-I-HF-DZHK24 (NCT04634266) is an investigator-initiated, prospective, randomized, open-label, multicentre strategy trial. Approximately 360 patients with severe TR and manifest right-sided HF will be enrolled. In contrast to previous trials, subjects with increased risk for HFH will be selected as facilitated by specific inclusion criteria: HFH in the previous year, or presence of cardio-renal syndrome, or evidence for cardio-hepatic syndrome. Subjects will be randomized 2:1 to TTVI and optimal medical therapy (OMT) or continuation of OMT alone. All CE-marked transcatheter repair devices including tricuspid transcatheter edge-to-edge repair (T-TEER) or transcatheter tricuspid annuloplasty can be used for TTVI. The participating 29 study sites are highly experienced and treated a mean of 176 patients in 4.5 years with T-TEER before study activation. The primary outcome will be assessed at 1 year. First, a composite of all-cause mortality, HFH, and QoL improvement will be tested hierarchically. If positive, the combination of hard clinical endpoints including all-cause mortality and HFH will be tested. Patients will be followed for a total of 3 years. The safety outcome comprises complications of TTVI, life-threatening bleeding and death.

Conclusions

The TRIC-I-HF-DZHK24 trial will define the role of TTVI in patients with severe TR and right-sided HF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiac CatheterizationHeart FailureHeart Valve Prosthesis ImplantationQuality of LifeTricuspid ValveTricuspid Valve InsufficiencyFemaleHumansMaleProspective StudiesRandomized Controlled Trials as TopicTreatment OutcomeMulticenter Studies as Topic

Stichwörter der Autor:innen

Heart failureManifest right‐sided heart failureOptimal medical therapyTranscatheter tricuspid valve interventionTricuspid regurgitationTricuspid transcatheter edge‐to‐edge repair

Autor:innen und Institutionen

  • Department of Cardiology, Department of Medicine I, LMU University Hospital, LMU Munich, Munich, Germany.
  • German Center for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany.
  • Department of Cardiology and Angiology, Eberhard Karls University Tübingen, Tübingen, Germany.
  • Department of Cardiology, University Heart Center, Ulm, Germany.
  • Department of Internal Medicine and Cardiology, Katholisches Marienkrankenhaus, Hamburg, Germany.
  • University Heart Center, Schleswig-Holstein University, Lübeck, Germany.

Zitieren

APA

Stocker, T. J., Geisler, T., Rottbauer, W., Lubos, E., Frerker, C., Schofer, N., Frank, J., von Bardeleben, R. S., Kister, T., Osteresch, R., Lauten, A., Rassaf, T., Rothe, J., Leistner, D. M., Stolz, L., Kehl, V., Grzeschniok, M., Hagendorff, A., Rudolph, V., …, & TRIC‐I‐HF‐DZHK24 Investigators (2025). Rationale and Design of the TRIC-I-HF-DZHK24 (TRICuspid Intervention in Heart Failure) Trial. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3795

Vancouver

Stocker TJ, Geisler T, Rottbauer W, Lubos E, Frerker C, Schofer N, et al. Rationale and Design of the TRIC-I-HF-DZHK24 (TRICuspid Intervention in Heart Failure) Trial. European Journal of Heart Failure. 2025. doi:10.1002/ejhf.3795

BibTeX
@article{Stocker2025,
  author = {Stocker, Thomas J and Geisler, Tobias and Rottbauer, Wolfgang and Lubos, Edith and Frerker, Christian and Schofer, Niklas and Frank, Johanne and von Bardeleben, Ralph Stephan and Kister, Tobias and Osteresch, Rico and Lauten, Alexander and Rassaf, Tienush and Rothe, Jürgen and Leistner, David M and Stolz, Lukas and Kehl, Victoria and Grzeschniok, Maria and Hagendorff, Andreas and Rudolph, Volker and Baldus, Stephan and Lurz, Philipp and Massberg, Steffen and Hausleiter, Jörg and TRIC‐I‐HF‐DZHK24 Investigators, TRIC‐I‐HF‐DZHK24 Investigators},
  title = {Rationale and Design of the TRIC-I-HF-DZHK24 (TRICuspid Intervention in Heart Failure) Trial},
  journal = {European Journal of Heart Failure},
  year = {2025},
  doi = {10.1002/ejhf.3795}
}
Kostenlos starten →